Baiyue Biopharmaceutical

Baiyue Biopharmaceutical is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of next-generation antibody therapeutics for oncology. The company utilizes its proprietary platform to design and engineer monoclonal and bispecific antibodies that target complex biological pathways, including the CD47-SIRPα axis and Claudin 18.2. Its lead candidate, BY001, is a humanized monoclonal antibody targeting CD47, designed with reduced hemagglutination to improve safety profiles during treatment of solid and liquid tumors. Baiyue is committed to advancing its pipeline through clinical trials in both China and the United States to address significant unmet needs in cancer treatment. The company's R&D focus also extends to innovative bispecific formats targeting PD-L1 and TGF-β to overcome tumor immune evasion.